Clément Bonnet

454 total citations
34 papers, 234 citations indexed

About

Clément Bonnet is a scholar working on General Health Professions, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Clément Bonnet has authored 34 papers receiving a total of 234 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in General Health Professions, 7 papers in Pulmonary and Respiratory Medicine and 5 papers in Pathology and Forensic Medicine. Recurrent topics in Clément Bonnet's work include Health, Medicine and Society (8 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Cancer Genomics and Diagnostics (4 papers). Clément Bonnet is often cited by papers focused on Health, Medicine and Society (8 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Cancer Genomics and Diagnostics (4 papers). Clément Bonnet collaborates with scholars based in France, Spain and United States. Clément Bonnet's co-authors include Nicolas Mounier, Stéphane Vignot, Benoît Brouard, Richard Delarue, Emmanuel Itti, M Roques, Hervé Tilly, R. Hustinx, Philippe Gaulard and Stéphanie Becker and has published in prestigious journals such as Journal of Clinical Oncology, American Journal of Obstetrics and Gynecology and Annals of Oncology.

In The Last Decade

Clément Bonnet

22 papers receiving 220 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Clément Bonnet France 8 73 70 53 53 36 34 234
Waseem Khaliq United States 11 113 1.5× 58 0.8× 32 0.6× 41 0.8× 11 0.3× 51 322
Yi-Ting Hwang Taiwan 9 157 2.2× 18 0.3× 59 1.1× 52 1.0× 20 0.6× 10 336
Per-Olof Thuresson Switzerland 8 85 1.2× 31 0.4× 27 0.5× 98 1.8× 23 0.6× 22 390
Matthew I. Kim United States 13 59 0.8× 39 0.6× 38 0.7× 20 0.4× 65 1.8× 19 678
Monica Hagan Vetter United States 11 62 0.8× 12 0.2× 50 0.9× 29 0.5× 13 0.4× 33 480
Marianne S. Hom United States 12 90 1.2× 17 0.2× 9 0.2× 38 0.7× 11 0.3× 28 364
Khalil Al‐Farsi Oman 11 55 0.8× 43 0.6× 18 0.3× 27 0.5× 22 0.6× 35 329
Michael Solomon United States 9 39 0.5× 8 0.1× 83 1.6× 33 0.6× 42 1.2× 20 322
Khaldoon Aljerian Saudi Arabia 10 41 0.6× 20 0.3× 34 0.6× 40 0.8× 67 1.9× 50 298
Hadi Bhurgri Pakistan 13 159 2.2× 48 0.7× 21 0.4× 71 1.3× 27 0.8× 28 394

Countries citing papers authored by Clément Bonnet

Since Specialization
Citations

This map shows the geographic impact of Clément Bonnet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Clément Bonnet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Clément Bonnet more than expected).

Fields of papers citing papers by Clément Bonnet

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Clément Bonnet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Clément Bonnet. The network helps show where Clément Bonnet may publish in the future.

Co-authorship network of co-authors of Clément Bonnet

This figure shows the co-authorship network connecting the top 25 collaborators of Clément Bonnet. A scholar is included among the top collaborators of Clément Bonnet based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Clément Bonnet. Clément Bonnet is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kfoury, Maria, Clément Bonnet, Nicolas Delanoy, et al.. (2024). Dynamic changes in TP53 mutated circulating tumor DNA predicts outcome of patients with high-grade ovarian carcinomas. International Journal of Gynecological Cancer. 34(11). 1836–1839.
2.
Gruel, Nadège, Dimitri Tzanis, Sylvie Bonvalot, et al.. (2023). MDM4 amplification in atypical lipomatous tumors/well‐differentiated liposarcoma: Private event or alternative oncogenic mechanism?. Genes Chromosomes and Cancer. 62(6). 367–372. 4 indexed citations
3.
Crichi, Benjamin, Christine Le Maignan, Clément Bonnet, et al.. (2021). Patient education program at the forefront of cancer-associated thrombosis care. JMV-Journal de Médecine Vasculaire. 46(5-6). 215–223. 4 indexed citations
4.
Ursu, Rénata, Jérôme LeGoff, Stéphanie Harel, et al.. (2020). 1721P Prolonged positive SARS-CoV-2 RT-PCR in cancer outpatients requires specific reorganization of cancer centres. Annals of Oncology. 31. S1010–S1010. 1 indexed citations
5.
6.
Crichi, Benjamin, Claire Montlahuc, Clément Bonnet, et al.. (2020). How to treat venous thromboembolism (TVE) in cancer patients: ten years of multidisciplinary team meetings (MDTM) at Saint-Louis Hospital. JMV-Journal de Médecine Vasculaire. 45(6). 6S24–6S30. 2 indexed citations
7.
Crichi, Benjamin, et al.. (2020). Drug-drug interaction (DDI) with direct oral anticoagulant (DOAC) in patients with cancer. JMV-Journal de Médecine Vasculaire. 45(6). 6S31–6S38. 9 indexed citations
8.
Bigot, Frédéric, Clément Bonnet, & Christophe Massard. (2017). Les avancées de l’immunothérapie dans la prise en charge des patients atteints de tumeurs génito-urinaires. Bulletin du Cancer. 104(4). 370–379.
9.
Bonnet, Clément, Pascaline Boudou‐Rouquette, Olivier Huillard, et al.. (2017). Potential drug–drug interactions with abiraterone in metastatic castration-resistant prostate cancer patients: a prevalence study in France. Cancer Chemotherapy and Pharmacology. 79(5). 1051–1055. 16 indexed citations
10.
Bernard‐Tessier, Alice, et al.. (2017). Atézolizumab (Tecentriq ® ) : activité, indication et modalités d’utilisation dans les carcinomes urothéliaux localement avancés ou métastatiques. Bulletin du Cancer. 105(2). 140–145. 14 indexed citations
11.
Bigot, Frédéric, Antoine Hollebecque, Alberto Carmona‐Bayonas, et al.. (2016). Identification of new prognostic factors in phase I patients treated by immunotherapy. Annals of Oncology. 27. vi124–vi124. 2 indexed citations
12.
Cottereau, Anne‐Ségolène, Stéphanie Becker, Florence Broussais, et al.. (2016). Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET/CT in patients with peripheral T-cell lymphoma (PTCL). Annals of Oncology. 27(4). 719–724. 75 indexed citations
13.
Bonnet, Clément, Guillaume Beinse, Luc Cabel, et al.. (2016). ESMO ECCO 2015 : les temps forts de l’immunothérapie et des thérapies ciblées. Bulletin du Cancer. 103(6). 594–603. 2 indexed citations
14.
Brouard, Benoît, et al.. (2014). E-santé et m-santé: état des lieux en 2014 et apports potentiels en oncologie. Bulletin du Cancer. 101(10). 940–950. 11 indexed citations
15.
Bonnet, Clément, et al.. (2008). Les enjeux de l'emploi pour les personnes handicapées psychiques. L information psychiatrique. Volume 84(9). 835–840. 1 indexed citations
16.
Bonnet, Clément, et al.. (2008). Les enjeux de l'emploi pour les personnes handicapées psychiques. L information psychiatrique. 84(9). 835–835.
17.
Bonnet, Clément. (2002). De la circulaire de février 1958 à la loi de mars 2002. Cairn.info. 249–254. 2 indexed citations
18.
Bonnet, Clément, et al.. (2001). Immunotherapy units: a follow-up study.. PubMed. 11(3). 167–71. 4 indexed citations
19.
Fombonne, Éric, et al.. (1995). Emploi et psychose : à propos d'une étude descriptive : Ce qu'il en coûte. 71(4). 377–382. 1 indexed citations
20.
Sever, J. L., et al.. (1966). Toxoplasmosis, antibody level, and pregnancy outcome. American Journal of Obstetrics and Gynecology. 95(6). 809–816. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Waseem Khaliq Breakdown of academic impact, for papers by Yi-Ting Hwang Breakdown of academic impact, for papers by Per-Olof Thuresson Breakdown of academic impact, for papers by Matthew I. Kim Breakdown of academic impact, for papers by Monica Hagan Vetter Breakdown of academic impact, for papers by Marianne S. Hom Breakdown of academic impact, for papers by Khalil Al‐Farsi Breakdown of academic impact, for papers by Michael Solomon Breakdown of academic impact, for papers by Khaldoon Aljerian Breakdown of academic impact, for papers by Hadi Bhurgri
Rankless by CCL
2026